Graph Therapeutics Brings Total Funding to Over $10 Million to Advance Therapeutics Programs in Inflammation and Immunology

Vienna, Austria — 22 June 2026 — Graph Therapeutics (“Graph”) announces that Daphni, the Paris-based venture capital firm, has joined Graph’s investor syndicate to accelerate its internal pipeline. Daphni invests alongside continued participation from existing investors SquareOne, Merantix Capital, and NAVEC Investment Management, with additional non-dilutive grant funding provided by the Austrian Research Promotion Agency (FFG) and the Austria Wirtschaftsservice (AWS). This new investment of $5M brings Graph’s total funding to date to over $10 million including non-dilutives.

Graph is advancing its internal drug discovery programs across multiple inflammatory and immune-mediated disease indications. This push is powered by platform infrastructure that has been substantially de-risked and validated across clinically relevant biological models. The maturity of Graph's platform also positions the company to pursue strategic out-licensing opportunities and partnerships, translating platform validation into value beyond its own pipeline. Daphni joins the existing group of investors in supporting Graph's mission to decode complex immune dysfunction at scale and translate it into differentiated medicines.

"Graph’s platform has reached a critical inflection point as we are now generating actionable biological insights that directly inform our own drug discovery programs," said Gregory Vladimer, PhD, co-founder and CEO of Graph Therapeutics. "Daphni's conviction in our approach is a powerful signal as we begin to scale investment into asset programs. With their support alongside our existing investors, we have both the backing and the urgency to pursue precision medicines in I&I, and to show the industry that rigorously decoding immune dysfunction in real patient cells reveals what actually drives disease.”

"Graph exemplifies the next generation of techbio: a company where deep technological innovation is inseparable from rigorous R&D, led by a team with a proven track record in precision medicine," said Sofia Dahoune, Partner at Daphni. "The complexity of immune-mediated diseases demands exactly this kind of integrated approach, and we are excited to support the GraphTx team as they move into therapeutics."

Graph's platform combines sophisticated live patient cell models with advanced machine learning to decode complex immune dysfunction. Building on the founding team's experience pioneering AI-driven precision oncology at Allcyte (acquired by Exscientia), Graph applies its lab-in-the-loop perturbation approach to primary patient cell samples and multi-omics data to identify disease mechanisms, drug targets, and biomarkers for immune-mediated diseases.

The company's total funding to date includes non-dilutive grant awards from Austria's leading innovation agencies including the FFG's Austrian Life Sciences program and the AWS Deep Tech Life Sciences Seed Financing program. These awards reflect independent validation of Graph's scientific approach and the strength of Austria's public funding ecosystem for deep tech life sciences companies.